Literature DB >> 26526953

Trypanosoma cruzi infection induces the expression of CD40 in murine cardiomyocytes favoring CD40 ligation-dependent production of cardiopathogenic IL-6.

Mariela Alejandra Moreno Ayala1,2, Agustina Casasco1,3, Mariela González4, Miriam Postan4, Ricardo Santiago Corral1, Patricia Beatriz Petray5,6.   

Abstract

The inflammatory response in the myocardium is an important aspect of the pathogenesis of Chagas' heart disease raised by Trypanosoma cruzi. CD40, a transmembrane type I receptor belonging to the tumor necrosis factor receptor (TNFR) family, is expressed in a broad spectrum of cell types and is crucial in several inflammatory and autoimmune diseases. Activation of CD40 through ligation to CD40L (CD154) induces multiple effects, including the secretion of proinflammatory molecules. In the present study, we examined the ability of T. cruzi to trigger the expression of CD40 in cardiac myocytes in vitro and in a murine model of chagasic cardiomyopathy. Our results indicate, for the first time, that T. cruzi is able to induce the expression of CD40 in HL-1 murine cardiomyocytes. Moreover, ligation of CD40 receptor upregulated interleukin-6 (IL-6), associated with inflammation. Furthermore, the induction of this costimulatory molecule was demonstrated in vivo in myocardium of mice infected with T. cruzi. This suggests that CD40-bearing cardiac muscle cells could interact with CD40L-expressing lymphocytes infiltrating the heart, thus contributing to inflammatory injury in chagasic cardiomyopathy.

Entities:  

Keywords:  CD40; Cardiomyocytes; Chagas’ disease; Trypanosoma cruzi

Mesh:

Substances:

Year:  2015        PMID: 26526953     DOI: 10.1007/s00436-015-4805-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  30 in total

1.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Authors:  W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 2.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

3.  Toll-like receptor-2 and interleukin-6 mediate cardiomyocyte protection from apoptosis during Trypanosoma cruzi murine infection.

Authors:  Nicolás Eric Ponce; Roxana Carolina Cano; Eugenio Antonio Carrera-Silva; Ana Paula Lima; Susana Gea; Maria Pilar Aoki
Journal:  Med Microbiol Immunol       Date:  2011-10-09       Impact factor: 3.402

4.  Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite.

Authors:  M A Campos; I C Almeida; O Takeuchi; S Akira; E P Valente; D O Procópio; L R Travassos; J A Smith; D T Golenbock; R T Gazzinelli
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

Review 5.  Chemokines, inflammation and Trypanosoma cruzi infection.

Authors:  Mauro M Teixeira; Ricardo T Gazzinelli; João S Silva
Journal:  Trends Parasitol       Date:  2002-06

6.  Induction of the formyl peptide receptor 2 in microglia by IFN-gamma and synergy with CD40 ligand.

Authors:  Keqiang Chen; Pablo Iribarren; Jian Huang; Lingzhi Zhang; Wanghua Gong; Edward H Cho; Stephen Lockett; Nancy M Dunlop; Ji Ming Wang
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Timing of expression of inflammatory mediators in skeletal muscles from mice acutely infected with the RA strain of Trypanosoma cruzi.

Authors:  Romina Andrea Cutrullis; Miriam Postan; Patricia Beatriz Petray; Ricardo Santiago Corral
Journal:  Pathobiology       Date:  2009-06-29       Impact factor: 4.342

8.  The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection.

Authors:  Ali Ouaissi; Eliane Guilvard; Yves Delneste; Gersende Caron; Giovanni Magistrelli; Nathalie Herbault; Nathalie Thieblemont; Pascale Jeannin
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

9.  Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production.

Authors:  L Zhang; R L Tarleton
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

10.  Analysis of the dynamics of infiltrating CD4(+) T cell subsets in the heart during experimental Trypanosoma cruzi infection.

Authors:  Cristina Sanoja; Sofía Carbajosa; Manuel Fresno; Núria Gironès
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  4 in total

1.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  MiR-145-5p regulates hypoxia-induced inflammatory response and apoptosis in cardiomyocytes by targeting CD40.

Authors:  Ming Yuan; Liwei Zhang; Fei You; Jingyu Zhou; Yongjiang Ma; Feifei Yang; Ling Tao
Journal:  Mol Cell Biochem       Date:  2017-03-09       Impact factor: 3.396

Review 3.  The Role of Co-Stimulatory Molecules in Chagas Disease.

Authors:  Bruna F Pinto; Nayara I Medeiros; Tereza C M Fontes-Cal; Isabela M Naziazeno; Rodrigo Correa-Oliveira; Walderez O Dutra; Juliana A S Gomes
Journal:  Cells       Date:  2018-11-07       Impact factor: 6.600

4.  Interleukin-9 in Immunopathology of Trypanosoma cruzi Experimental Infection.

Authors:  Nadjania Saraiva de Lira Silva; Cristina Mary Orikaza; Fabiana Rodrigues de Santana; Luana Aguiar Dos Santos; Bruno Ramos Salu; Maria Luiza Vilela Oliva; Rita de Cássia Sinigaglia; Renato Arruda Mortara
Journal:  Front Cell Infect Microbiol       Date:  2021-10-15       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.